C

Changchun High & New Technology Industries Group Inc
SZSE:000661

Watchlist Manager
Changchun High & New Technology Industries Group Inc
SZSE:000661
Watchlist
Price: 93.65 CNY -0.38% Market Closed
Market Cap: 38.2B CNY

Changchun High & New Technology Industries Group Inc
Equity Earnings Affiliates

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Changchun High & New Technology Industries Group Inc
Equity Earnings Affiliates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Equity Earnings Affiliates CAGR 3Y CAGR 5Y CAGR 10Y
C
Changchun High & New Technology Industries Group Inc
SZSE:000661
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Changchun High & New Technology Industries Group Inc
Glance View

Market Cap
38.2B CNY
Industry
Pharmaceuticals

Changchun High & New Technology Industries Group Inc. (CHT) emerged as a key player in China's burgeoning pharmaceutical and medical device sector. Founded in 1993, it has consistently ridden the wave of technological innovation to establish itself as a prominent figure in the field. Located in the heart of Changchun, a city known for its industrial prowess, CHT has meticulously built its reputation by focusing on biopharmaceuticals, particularly those aimed at combating chronic diseases such as diabetes and cardiovascular ailments. With a robust pipeline of products and a strategic partnership with global pharmaceutical companies, CHT crafts its narrative around innovation and accessibility, striving to bring advanced healthcare solutions to a wider Chinese audience. The company's business model thrives on a dual approach: leveraging cutting-edge research and a solid manufacturing base. By investing heavily in research and development, CHT fuels the continual advancement of its pharmaceutical and medical product lines. Its revenues are predominantly drawn from two sources—pharmaceutical sales and medical device manufacturing, with the latter seeing a surge due to an increased demand for modern healthcare solutions in China. This strategic focus allows CHT not only to expand its domestic market footprint but also to push toward international arenas, positioning itself as a competitive global entity in the healthcare ecosystem. Through agile adaptation to market needs and steadfast adherence to quality, CHT continues to write its growth story in an industry marked by rapid transformation and intense competition.

Intrinsic Value
80.59 CNY
Overvaluation 14%
Intrinsic Value
Price
C

See Also

Back to Top